Prolonged REM Latency Potential Marker for Alzheimer Disease
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 27, 2025 -- Prolonged rapid eye movement (REM) latency may be a potential marker for Alzheimer disease and Alzheimer disease and related dementias (AD/ADRD), according to a study published online Jan. 27 in Alzheimer's & Dementia.
JIangli Jin, from the China-Japan Friendship Hospital in Beijing, and colleagues enrolled 128 adults (64 with Alzheimer disease, 41 with mild cognitive impairment, and 23 with normal cognition) to examine the relationship between sleep architecture and AD/ADRD. Participants underwent polysomnography, amyloid β (Aβ) positron emission tomography, and plasma biomarker analysis, including phosphorylated tau at threonine 181 (p‐tau181), neurofilament light, and brain‐derived neurotrophic factor (BDNF).
The researchers found that the highest versus the lowest tertile of REM latency was associated with higher Aβ burden, elevated p-tau181, and reduced BDNF levels (β = 0.08, 0.19, and −0.47, respectively) after adjustment for demographics, apolipoprotein E ε4 status, cognition, and comorbidities.
"Prolonged REM latency was associated with key AD/ADRD pathophysiology, including elevated Aβ deposition and plasma p-tau181 and lower BDNF levels," the authors write. "Given that these pathological changes typically precede clinical symptoms by a decade or more, our findings may provide novel insights regarding the involvement of REM sleep in the early detection and intervention of AD/ADRD."
One author disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...
Dementia Risk Does Not Differ With GLP-1 RAs, DPP4is for Seniors With T2DM
MONDAY, July 21, 2025 -- For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1...
Gabapentin for Back Pain Linked to Increased Risk for Dementia, MCI
FRIDAY, July 11, 2025 -- For adults with chronic low back pain, gabapentin prescription is associated with an increased risk for dementia and mild cognitive impairment (MCI)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.